Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow

Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

Olika bud om distansarbete – ”Vi ber vår personal att komma tillbaka till kontoret”

Hur viktigt är det för life science-bolagen att erbjuda distansarbete? Den frågan väckte debatt och fick många olika svar vid en paneldiskussion om talangrekryt...

ZEISS Smartzoom 100 for Inspection Efficiency

Catch up on our free webinar.

Mercodia AB

Licenspartner backar ur – lämnar tillbaka projekt till Affibody

Affibody får tillbaka de globala rättigheterna till izokibeb sedan samarbetspartnern Acelyrin avbrutit sin utveckling av programmet.

Norwegian cancer research companies merge

The Norwegian companies Ultimovacs and Zelluna Immunotherapy plan to merge. At the same time, it is made clear that Ultimovacs' CEO is leaving the company.

New moves around Nykode's management – withdrawal of resignations

Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.

ZEISS Insights: Measurement of bone plates and screws

Get free access to technical paper.

FDA approves first non-opioid pain reliever in over 20 years

For the first time in decades, a new type of acute pain medication that is not an opioid has been approved in the USA.

Moderna develops mRNA vaccine against norovirus

A highly anticipated vaccine is in late clinical evaluation and could be ready for approval within a couple of years. The target is the norovirus, often called ...

ZEISS presents the "Quality Innovation Days"

The digital event for metrology and software.

Thumbs down for lecanemab in the EU – “Very surprised”

The Azheimer's drug lecanemab has received a negative assessment from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), acc...

The First Multi-Technology System from ZEISS

Microscope and measuring machine in one.

Enhance your expertise with your measuring software

Discover the training options in our ZEISS Metrology Portal.

The physician at the tech giant: “Observations in the emergency room made my mind up”

When Nasim Farrokhnia was in third grade at school in Tehran, the capital of Iran, her father gave her a book about Marie Curie, which soon became her favourite...

Recipharm divests five Swedish plants

Swedish contract manufacturer Recipharm is selling its facilities in Solna, Strängnäs, Höganäs, Karlskoga and Uppsala OTC Development to US private equity compa...

Cost-efficient development of laboratory devices

8 ways to optimise development costs and speed up processes

ZEISS showcases expansion of ophthalmic care options creating industry-leading workflow solutions

ZEISS Medical Technology will showcase new ophthalmic innovations and market milestones at ESCRS 2025 in Copenhagen.

Settlement of cancer allegations against blockbuster drug

French pharmaceutical company Sanofi has reached a principal agreement in the US on around 4,000 of the cases in which its now withdrawn blockbuster heartburn d...

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...

Positive EMA Decision for BioArctic's New Drug Candidate

Bioarctic's drug candidate for multiple system atrophy, exidavnemab, is recommended to be classified as an orphan drug, according to the European Medicines Agency (EMA).

The impact of the recession on the Swedish medtech sector

We need health care regardless of whether the economy is good or bad, but the current recession also affects the Medtech sector.

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...